Drug Development: Discovery/Preclinical of Novel Compounds

R01 (also available: R21)

Drug Discovery For Nervous System Disorders

This Funding Opportunity Announcement (FOA) encourages research grant applications directed toward the discovery and preclinical testing of novel compounds for the prevention and treatment of nervous system disorders.

Through this funding opportunity the National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Institute on Drug Abuse (NIDA) encourage the submission of research grant applications that aim to translate this wealth of basic science findings into the conceptualization, discovery, and preclinical evaluation of innovative therapeutics for mental illnesses, drug and alcohol abuse, and nervous system disorders associated with aging, with the goal of accelerating the development of new treatments for these diseases.


• Pre-Application Submission Deadline: 30 days before application submission due date
• Application Submission Deadline: 5:00 PM local time of applicant organization, Feb. 5, 2017; Jun. 5, 2017; Oct. 5, 2017; Feb. 5, 2018; Jun. 5, 2018; Oct. 5 2018

Companion funding opportunity:


Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.